혈관성형술용 풍선 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Angioplasty Balloons Market Size, Share & Trends Analysis Report By Product, By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,407,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,820,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,646,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

혈관성형술용 풍선 시장 성장과 동향

Grand View Research, Inc의 최신 보고서에 따르면, 혈관성형술용 풍선 세계 시장 규모는 2030년 34억 달러에 달할 것으로 예상되며, 2025-2030년 동안 연평균 3.8%의 성장률을 기록할 것으로 예상됩니다. 이러한 성장은 유리한 정부 정책과 관상동맥 및 말초 중재시술의 증가에 기인합니다. 혈관성형술은 최소침습적 시술이기 때문에 환자와 의사들은 고가의 스텐트 시술보다 혈관성형술을 선호하고 있습니다. 또한, 혈관성형술용 풍선의 발전과 지리적 범위의 확장은 향후 몇 년 동안 시장 성장을 촉진할 가능성이 높습니다.

예를 들어, 2014년 12월 Medtronic plc는 말초동맥질환 치료용 약물 코팅 풍선 IN.PACT Admiral에 대한 FDA 승인을 획득했습니다. TREK 및 MINI TREK, AngioSculpt, Flextome과 같은 커팅 스코어링 풍선의 승인 및 상용화, 그리고 신형 풍선의 채택 증가가 시장을 더욱 견인할 것으로 보입니다. 시장을 더욱 견인할 것으로 보입니다.

혈관성형술용 풍선 시장 하이라이트

• 일반 풍선이 2024년 53.8%의 가장 큰 시장 점유율을 차지한 것은 비용이 저렴하고 관상동맥 폐쇄를 치료할 수 있기 때문입니다.
• DEB는 재협착률 감소와 대기업의 R&D 투자 증가로 인해 예측 기간 동안 가장 빠르게 성장할 것으로 예상됩니다.
• 2024년에는 관상동맥 질환 부문이 53.4%의 가장 큰 시장 점유율을 차지했습니다. 관상동맥 질환은 모든 심장 질환 중 가장 흔한 질환으로 발병률이 높기 때문입니다.
• 외래 수술 센터 부문은 2024년 38.8%의 점유율로 시장을 장악했습니다.
• 북미 혈관성형술용 풍선 시장은 2024년 세계 시장에서 39.1%의 점유율을 차지하며 중요한 위치를 차지하고 있습니다. 북미는 혈관성형술용 풍선 시장에서 지배적인 지역이며, 선진화된 의료 인프라, 높은 의료비, 고령 인구의 증가가 그 요인으로 작용하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 혈관성형술용 풍선 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 혈관성형 풍선 시장 분석 툴
  • 산업 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 혈관성형술용 풍선 시장 : 제품별, 추정·동향 분석

• 세계의 혈관성형술용 풍선 시장 : 제품 대시보드
• 세계의 혈관성형술용 풍선 시장 : 제품 변동 분석
• 세계의 혈관성형술용 풍선 시장(제품별, 매출별)
• 일반 풍선
• 약제 코팅 풍선
• 커팅 풍선
• 스코어링 풍선

제5장 혈관성형술용 풍선 시장 : 용도별, 추정·동향 분석

• 세계의 혈관성형술용 풍선 시장 : 용도 대시보드
• 세계의 혈관성형술용 풍선 시장 : 용도 변동 분석
• 세계의 혈관성형술용 풍선 시장(용도별, 매출별)
• 말초혈관질환
• 관상동맥질환

제6장 혈관성형술용 풍선 시장 : 최종 용도별, 추정·동향 분석

• 세계의 혈관성형술용 풍선 시장 : 최종 용도 대시보드
• 세계의 혈관성형술용 풍선 시장 : 최종 용도 변동 분석
• 세계의 혈관성형술용 풍선 시장(용도별, 매출별)
• 외래 수술 센터
• 병원
• 카테터 검사실

제7장 혈관성형술용 풍선 시장 : 국가, 제품, 용도, 최종 용도에 의한 지역별, 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 구도

• 주요 제조업체에 의한 최근 동향과 영향 분석
• 기업/경쟁 분류
• 벤더 상황
  • 주요 판매대리점과 채널 파트너 리스트
  • 주요 기업의 시장 점유율 분석, 2024년
• 기업 개요
  • Medtronic
  • Boston Scientific Corporation
  • Johnson & Johnson Services, Inc.
  • Abbott
  • CR Bard, Inc.
  • Spectranetics
  • Terumo Medical Corporation
  • Cardinal Health
  • BIOTRONIK
  • Cook Medical
  • ENDOCOR GmbH
  • B. Braun SE

ksm

영문 목차

영문목차

Angioplasty Balloons Market Growth & Trends:

The global angioplasty balloons market size is expected to reach USD 3.4 billion in 2030 and is projected to grow at a CAGR of 3.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is attributed to favorable government policies and increasing coronary and peripheral interventions. Angioplasty is a minimally invasive procedure, hence patients and surgeons prefer this procedure over high-cost stent placements. Furthermore, advancements in angioplasty balloons and expanding geographical reach are likely to propel the market growth in the coming years.

For instance, in December 2014, Medtronic plc received an FDA approval for their drug-coated balloon IN.PACT Admiral for the treatment of peripheral artery disease. The company also received product approval from Japanese Ministry of Health, Labor and Welfare for the treatment of peripheral artery disease in the upper leg. Approval and commercialization of cutting and scoring balloons, such as TREK and MINI TREK, AngioSculpt, and Flextome balloons along with rising adoption of new balloons are likely to drive the market further.

Angioplasty Balloons Market Report Highlights:

• The normal balloons segment held the largest market share of 53.8% in 2024 due to low costs and ability of these products to treat coronary artery obstruction
• DEBs are anticipated to be the fastest-growing segment during the forecast period due to lower restenosis rate and increased R&D investments by major companies
• In 2024, coronary vascular diseases segment held the largest market share of 53.4% due to the high incidence of coronary artery diseases, which are the most common type of all heart diseases
• The ambulatory surgery centers segment dominated the market with a share of 38.8% in 2024, due to the huge demand for treatments in these settings.
• North America angioplasty balloons market held a significant position in the global market in 2024, with a share of 39.1%. North America has been a dominant region in the angioplasty balloons market, driven by advanced healthcare infrastructure, high healthcare spending, and a growing elderly population

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. End Use outlook
• 2.3. Competitive Insights

Chapter 3. Angioplasty Balloons Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of cardiovascular diseases
    • 3.2.1.2. Technological advancements in balloon design
    • 3.2.1.3. Minimally invasive procedures and cost efficiency.
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of angioplasty procedures
    • 3.2.2.2. Risk of complications and re-stenosis
• 3.3. Angioplasty Balloons Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Angioplasty Balloons Market: Product Estimates & Trend Analysis

• 4.1. Global Angioplasty Balloons Market: Product Dashboard
• 4.2. Global Angioplasty Balloons Market: Product Movement Analysis
• 4.3. Global Angioplasty Balloons Market by Product, Revenue
• 4.4. Normal Balloons
  • 4.4.1. Normal balloons market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.5. Drug Coated Balloons
  • 4.5.1. Drug coated balloons market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.6. Cutting Balloons
  • 4.6.1. Cutting balloons market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.7. Scoring Balloons
  • 4.7.1. Scoring balloons market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Angioplasty Balloons Market: Application Estimates & Trend Analysis

• 5.1. Global Angioplasty Balloons Market: Application Dashboard
• 5.2. Global Angioplasty Balloons Market: Application Movement Analysis
• 5.3. Global Angioplasty Balloons Market by Application, Revenue
• 5.4. Peripheral Vascular Diseases
  • 5.4.1. Peripheral vascular diseases market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.5. Coronary Vascular Diseases
  • 5.5.1. Coronary vascular diseases market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Angioplasty Balloons Market: End Use Estimates & Trend Analysis

• 6.1. Global Angioplasty Balloons Market: End Use Dashboard
• 6.2. Global Angioplasty Balloons Market: End Use Movement Analysis
• 6.3. Global Angioplasty Balloons Market by End Use, Revenue
• 6.4. Ambulatory Surgery Centers
  • 6.4.1. Ambulatory surgery centers market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.5. Hospitals
  • 6.5.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.6. Cath Labs
  • 6.6.1. Cath Labs market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Angioplasty Balloons Market: Regional Estimates & Trend Analysis by Country, Product, Application and End Use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Manufacturers
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. Medtronic
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Boston Scientific Corporation
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Johnson & Johnson Services, Inc.
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Abbott
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. C. R. Bard, Inc.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Spectranetics
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Terumo Medical Corporation
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Cardinal Health
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. BIOTRONIK
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Cook Medical
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives
  • 8.4.11. ENDOCOR GmbH
    • 8.4.11.1. Company overview
    • 8.4.11.2. Financial performance
    • 8.4.11.3. Product benchmarking
    • 8.4.11.4. Strategic initiatives
  • 8.4.12. B. Braun SE
    • 8.4.12.1. Company overview
    • 8.4.12.2. Financial performance
    • 8.4.12.3. Product benchmarking
    • 8.4.12.4. Strategic initiatives

관련자료